Compound Evidence File
#EC-2026-0534
Finasteride
Filed under Oral Tablets. The bureau holds 152 laboratory returns for this compound from 44 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
44 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 10.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 19 Feb 2026 | 5 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 26 May 2026 | 17 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Jun 2026 | 15 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 24 Jun 2026 | 18 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Feb 2026 | 10 Mar 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 22 Dec 2025 | 10 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 14 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Jan 2026 | 27 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Mar 2026 | 14 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Feb 2026 | 11 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Apr 2026 | 20 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Dec 2025 | 7 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 9.9 | 21 May 2026 | 9 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 9.9 | 24 Dec 2025 | 25 Apr 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 9.9 | 9.9 | 10.0 | 21 Mar 2026 | 24 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 9.9 | 28 Dec 2025 | 11 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Apr 2026 | 2 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 9.9 | 22 Jun 2026 | 10 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 9.9 | 9 Aug 2026 | 13 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 6 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 9.9 | 10 Apr 2026 | 3 Aug 2026 |
| M-PeptidesCASE #VI-2026-0442 | X | 1 | 9.5 | 9.5 | 9.5 | 7 May 2025 | 7 May 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 9.0 | 7.3 | 10.0 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.9 | 8.4 | 9.9 | 25 May 2026 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 8.8 | 7.6 | 10.0 | 23 May 2026 | 23 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 6 | 8.7 | 7.6 | 10.0 | 13 Jun 2025 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.4 | 6.9 | 9.6 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.4 | 7.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Atomik LabzCASE #VI-2026-0327 | X | 3 | 8.3 | 7.4 | 8.9 | 16 Mar 2025 | 24 May 2026 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 8.2 | 8.2 | 8.2 | 17 Dec 2024 | 17 Dec 2024 |
| Reta-PeptideCASE #VI-2026-0756 | X | 6 | 7.6 | 6.4 | 9.4 | 27 Feb 2025 | 19 Jan 2026 |
| HK PeptidesCASE #VI-2026-0140 | X | 9 | 7.4 | 5.1 | 9.7 | 27 Feb 2025 | 21 May 2026 |
| Peptide CraftersCASE #VI-2026-0994 | X | 1 | 7.4 | 7.4 | 7.4 | 2 Jul 2025 | 2 Jul 2025 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 7.4 | 7.4 | 7.4 | 3 Jun 2025 | 3 Jun 2025 |
| YimeiCASE #VI-2026-0081 | X | 2 | 7.2 | 6.1 | 8.3 | 24 Apr 2025 | 17 May 2026 |
| Peptide SciencesCASE #VI-2026-0867 | X | 12 | 6.6 | 5.1 | 8.1 | 27 Feb 2025 | 23 May 2026 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 6.4 | 6.4 | 6.4 | 20 Jun 2025 | 20 Jun 2025 |
| BeiBangAnCASE #VI-2026-0899 | X | 2 | 6.3 | 4.7 | 8.0 | 8 Jul 2025 | 21 May 2026 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 4.6 | 4.6 | 4.6 | 6 May 2025 | 6 May 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 3.6 | 3.6 | 3.6 | 11 Jun 2025 | 11 Jun 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 3 | 3.2 | 2.2 | 4.1 | 14 Jan 2025 | 19 Jan 2026 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Finasteride alone.